Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Would you consider anti-CD20 agents for treatment of multiple sclerosis in patients with history of breast cancer?
Related Questions
What is your treatment approach to neuropsychiatric symptoms secondary to lupus?
Can you use a JAK inhibitor and Mavenclad in a patient with both multiple sclerosis and rheumatoid arthritis?
How do you mitigate the risk of rebound disease activity when discontinuing S1p inhibitors or Tysabri in patients with multiple sclerosis?
How do you interpret the results of oligoclonal bands ordered to evaluate for demyelinating disease in patients with brain MRI lesions of unclear etiology?
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
What do you consider when deciding to use a high-efficacy DMT as an initial treatment in multiple sclerosis?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
When do you start cyclophosphamide for the treatment of anti-NMDA receptor encephalitis?
How do you decide on initial and sequential anti-CD20 therapy for patients with multiple sclerosis given the availability of rituximab, ocrelizumab, ublituximab, and ofatumumab?
How do you workup patients with neuropathy suspected to be secondary to sarcoid?
